An Expanding Patient Population and the Launches of Several Premium-Priced Branded Agents Will Contribute to the Growth of Russia’s Prostate Cancer Drug Market

An Expanding Patient Population and the Launches of Several Premium-Priced Branded Agents Will Contribute to the Growth of Russia’s Prostate Cancer Drug Market

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the total number of diagnosed incident cases of prostate cancer in Russia will increase at five percent annually from 2011 to 2016, driven mostly by an aging population and the rising number of disease diagnoses. According to , the expanding patient population will largely contribute to the growth of the Russia’s prostate cancer drug market, which is forecasted to grow six percent annually over the next ten years.

Report findings also reveal that a gradual increase and continued use of branded luteinizing hormone-releasing hormone (LHRH) agonists, such as AstraZeneca’s Zoladex and Pharm-Sintez's Buserelin, will supplement prostate cancer market growth in Russia through 2016. LHRH agonists and antiandrogens are the most commonly prescribed agents for localized and metastatic patients, in addition to prescribed chemotherapy for the latter patient group. Among uses of hormonal agents for the treatment of prostate cancer, branded LHRH agonists will partially replace lower-priced, generically available antiandrogens, particularly the monotherapy regimens. This change will parallel the shift in medical practice that has already taken place in the major markets.

“As is the case in the major markets, LHRH agonists and antiandrogens are by far the most frequently prescribed therapies for treatment across all stages of prostate cancer in Russia, with locally manufactured Buserelin as the most popular LHRH-agonist,” said Decision Resources Analyst Natalia Reoutova, M.A., M.Sc. “However, as the disease progresses, we’ve found that Russian oncourologists are more likely to resort to chemotherapy after the first-line hormonal treatment fails.”

The report also forecasts the launch of three novel branded agents in Russia throughout the next five years – Takeda/Millenium’s orteronel, Medivation/Astellas’ Xtandi (enzalutamide) and Algeta/Bayer Healthcare’s radium-223 (Alpharadin). Together with the recent approvals of Sanofi’s Jevtana (cabazitaxel) and Johnson & Johnson/Janssen’s Zytiga (abiraterone), these therapies are expected to contribute 19 percent of total market sales in 2016.

The new report features extensive primary research with Russian oncourologists as well as a market outlook by drug and class through 2016 and prostate cancer epidemiology through 2021.

Decision Resources is the first and only company to offer a syndicated report series for with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.

Decision Resources () is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.